Funds › Great Point Partners LLC
Great Point Partners LLC
13F for Q2 2026, filed Aug 14, 2026. 37 positions worth $529.1M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Great Point Partners LLC in the latest 13F quarter?
Using 13F.ai, how has Great Point Partners LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Great Point Partners LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | VOR Vor Biopharma Inc. | 1.70M | $31.3M | 5.9% | -2.9% | 13F ↗ |
| 2 | ABVX Abivax SA · ADR | 204,314 | $27.2M | 5.1% | New | 13F ↗ |
| 3 | VERA Vera Therapeutics, Inc. | 600,836 | $25.8M | 4.9% | +201% | 13F ↗ |
| 4 | ZURA Zura Bio Limited | 4.22M | $24.9M | 4.7% | Unchanged | 13F ↗ |
| 5 | ALMS Alumis Inc. | 856,061 | $24.1M | 4.6% | Unchanged | 13F ↗ |
| 6 | SLGL Sol-Gel Technologies Ltd. | 274,363 | $20.3M | 3.8% | Unchanged | 13F ↗ |
| 7 | DFTX Definium Therapeutics, Inc. | 425,000 | $20.0M | 3.8% | New | 13F ↗ |
| 8 | ANNX Annexon, Inc. | 3.50M | $20.0M | 3.8% | +40.0% | 13F ↗ |
| 9 | ORKA Oruka Therapeutics, Inc. | 183,330 | $17.4M | 3.3% | Unchanged | 13F ↗ |
| 10 | MLTX MoonLake Immunotherapeutics | 855,813 | $16.7M | 3.1% | +71.2% | 13F ↗ |
| 11 | SGMT Sagimet Biosciences Inc. | 2.03M | $15.7M | 3.0% | New | 13F ↗ |
| 12 | CTNM Contineum Therapeutics, Inc. | 921,481 | $15.1M | 2.9% | +15.2% | 13F ↗ |
| 13 | IMMX Immix Biopharma, Inc. | 1.28M | $13.2M | 2.5% | +265% | 13F ↗ |
| 14 | CLYM Climb Bio, Inc. | 1.00M | $13.0M | 2.5% | -25.0% | 13F ↗ |
| 15 | AMLX Amylyx Pharmaceuticals, Inc. | 700,000 | $12.6M | 2.4% | -60.0% | 13F ↗ |
| 16 | NKTR Nektar Therapeutics | 175,000 | $12.2M | 2.3% | -44.7% | 13F ↗ |
| 17 | NGNE Neurogene Inc. | 352,180 | $11.1M | 2.1% | -29.6% | 13F ↗ |
| 18 | LBRX LB Pharmaceuticals Inc | 317,221 | $10.3M | 1.9% | +5.7% | 13F ↗ |
| 19 | IRD Opus Genetics, Inc. | 1.97M | $8.1M | 1.5% | +507% | 13F ↗ |
| 20 | EPRX Eupraxia Pharmaceuticals Inc. · Com 298736 Al 3 Euronet Worldwide Inc Note 0.750% 3/1 | 1.20M | $7.9M | 1.5% | Unchanged | 13F ↗ |
| 21 | DRUG Bright Minds Biosciences Inc. | 109,603 | $7.7M | 1.5% | -50.2% | 13F ↗ |
| 22 | IFRX InflaRx N.V. | 3.05M | $6.8M | 1.3% | New | 13F ↗ |
| 23 | RLMD Relmada Therapeutics, Inc. | 842,106 | $5.8M | 1.1% | Unchanged | 13F ↗ |
| 24 | JATT JATT II Acquisition Corp | 500,000 | $5.7M | 1.1% | New | 13F ↗ |
| 25 | CGEM Cullinan Therapeutics, Inc. | 300,000 | $5.5M | 1.0% | Unchanged | 13F ↗ |
| 26 | ALT Altimmune, Inc. | 1.74M | $5.3M | 1.0% | New | 13F ↗ |
| 27 | AMAN Amanat Acquisition Corp | 500,000 | $5.1M | 1.0% | New | 13F ↗ |
| 28 | RZLT Rezolute, Inc. | 951,809 | $4.9M | 0.9% | Unchanged | 13F ↗ |
| 29 | SLN Silence Therapeutics Plc · ADR | 450,000 | $4.9M | 0.9% | -55.9% | 13F ↗ |
| 30 | PALI Palisade Bio, Inc. | 2.28M | $4.8M | 0.9% | -32.9% | 13F ↗ |
| 31 | EVMN Evommune, Inc. | 325,000 | $4.3M | 0.8% | Unchanged | 13F ↗ |
| 32 | SCYX SCYNEXIS, Inc. | 944,292 | $3.8M | 0.7% | New | 13F ↗ |
| 33 | ELVN Enliven Therapeutics, Inc. | 70,000 | $3.6M | 0.7% | New | 13F ↗ |
| 34 | HUMA Humacyte, Inc. | 3.75M | $2.9M | 0.6% | Unchanged | 13F ↗ |
| 35 | RNTX Rein Therapeutics, Inc. | 2.58M | $2.7M | 0.5% | New | 13F ↗ |
| 36 | DBVT DBV Technologies S.A. · ADR | 156,906 | $2.6M | 0.5% | New | 13F ↗ |
| 37 | PMN ProMIS Neurosciences Inc. | 86,150 | $1.1M | 0.2% | -76.8% | 13F ↗ |
Changes since Q1 2026
11 new, 7 added to, 9 trimmed, 13 exited, 10 unchanged. By estimated dollars.
New positions (11)
| ABVX Abivax SA · ADR | 204,314 | New | $27.2M |
| DFTX Definium Therapeutics, Inc. | 425,000 | New | $20.0M |
| SGMT Sagimet Biosciences Inc. | 2.03M | New | $15.7M |
| IFRX InflaRx N.V. | 3.05M | New | $6.8M |
| JATT JATT II Acquisition Corp | 500,000 | New | $5.7M |
| ALT Altimmune, Inc. | 1.74M | New | $5.3M |
| AMAN Amanat Acquisition Corp | 500,000 | New | $5.1M |
| SCYX SCYNEXIS, Inc. | 944,292 | New | $3.8M |
| ELVN Enliven Therapeutics, Inc. | 70,000 | New | $3.6M |
| RNTX Rein Therapeutics, Inc. | 2.58M | New | $2.7M |
Added to (7)
| VERA Vera Therapeutics, Inc. | 600,836 | +201% | $17.2M |
| IMMX Immix Biopharma, Inc. | 1.28M | +265% | $9.6M |
| MLTX MoonLake Immunotherapeutics | 855,813 | +71.2% | $6.9M |
| IRD Opus Genetics, Inc. | 1.97M | +507% | $6.8M |
| ANNX Annexon, Inc. | 3.50M | +40.0% | $5.7M |
| CTNM Contineum Therapeutics, Inc. | 921,481 | +15.2% | $2.0M |
| LBRX LB Pharmaceuticals Inc | 317,221 | +5.7% | $558.9K |
Trimmed (9)
| AMLX Amylyx Pharmaceuticals, Inc. | 700,000 | -60.0% | -$18.9M |
| NKTR Nektar Therapeutics | 175,000 | -44.7% | -$9.9M |
| DRUG Bright Minds Biosciences Inc. | 109,603 | -50.2% | -$7.7M |
| SLN Silence Therapeutics Plc · ADR | 450,000 | -55.9% | -$6.3M |
| NGNE Neurogene Inc. | 352,180 | -29.6% | -$4.6M |
| CLYM Climb Bio, Inc. | 1.00M | -25.0% | -$4.4M |
| PMN ProMIS Neurosciences Inc. | 86,150 | -76.8% | -$3.8M |
| PALI Palisade Bio, Inc. | 2.28M | -32.9% | -$2.3M |
| VOR Vor Biopharma Inc. | 1.70M | -2.9% | -$920.5K |
Exited (13)
| Apogee Therapeutics Inc | 374,000 | Exited | -$31.5M |
| Kalvista Pharmaceuticals Inc | 675,000 | Exited | -$13.6M |
| IMVT Immunovant, Inc. | 545,625 | Exited | -$13.6M |
| JBIO Jade Biosciences, Inc. | 964,462 | Exited | -$13.6M |
| ZBIO Zenas BioPharma, Inc. | 524,066 | Exited | -$10.2M |
| CMPX Compass Therapeutics, Inc. | 1.35M | Exited | -$7.1M |
| Scynexis Inc | 7.55M | Exited | -$6.9M |
| CNTX Context Therapeutics Inc. | 2.24M | Exited | -$5.9M |
| UNCY Unicycive Therapeutics, Inc. | 796,558 | Exited | -$5.2M |
| TENX Tenax Therapeutics, Inc. | 327,307 | Exited | -$5.2M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer